We are the global market leader in producing nuclear isotopes (medical isotopes). Every day, more than 30,000 patients worldwide depend on our medical substances for their treatment. These medical isotopes are used for medical imaging techniques (PET and SPECT scans). Doctors then use them in the treatment of cancer and heart and vascular disease for example.
Objective expertise. We can provide independent proof that an installation and process is in order. We guarantee nuclear top performance. Based on our knowledge and experience, we use nuclear solutions for people and the planet.
At the Energy & Health Campus in Petten, we have a unique combination of nuclear installations.
Our reactor in Petten is responsible for producing 35% of all medical isotopes worldwide and for 65% in Europe. This makes our reactor in Petten the biggest producer and supplier of isotopes in the world. With the development of isotopes from Petten, we help 30,000 people a day have a better life. This might be by detecting and treating cancer or for other disorders.
Visit our website 30000perdag.nl where we will be happy to tell you more.
Discover
Curious about all the facts and Fiction about Nuclear Energy?
Our 700 innovative and motivated employees are working towards a cancer-free world and a climate neutral energy supply.
The High Flux Reactor in Petten, from now on, produces only medical isotopes with low-enriched uranium. Until recently, the productions for NRG’s Belgian partner IRE were still based on high-enriched uranium, because IRE could not fully process low-enriched uranium. But now IRE has, partially, converted its chemical process to low-enriched uranium. This means that NRG can take the final step and end using high-enriched uranium in the HFR.
The Foundation NRG and the Foundation Preparation Pallas-reactor (PALLAS) intend to fuse together as one organisation, as announced by Bertholt Leeftink, CEO NRG/PALLAS, today during the New Year’s Toast. This spring, the proposal for the new organisation will be further detailed. “By combining our forces, we are able to make large steps forward in the development and production of nuclear medicines used for diagnostic purposes and for the treatment of patients suffering from life-threatening diseases. To this end, we need to establish a state-of-the art infrastructure that is being developed as we speak,” said Bertholt Leeftink.